1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising number of surgeries
4.2.2 Growing preference for single-dose administration of vaccines and drugs to treat chronic diseases
4.2.3 Increase in local LVP manufacturing
4.3 Market Restraints
4.3.1 Challenges in formulation of LVPs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Volume
5.1.1 100 ml - 250 ml
5.1.2 250 ml - 500 ml
5.1.3 500 ml - 1000 ml
5.1.4 1000 ml - 2000 ml
5.1.5 2000 ml and more
5.2 By Application
5.2.1 Therapeutic Injections
5.2.2 Fluid Balance Injections
5.2.3 Nutritious Injections
5.3 By Type of Packaging
5.3.1 Bottles
5.3.2 Bags
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Albert David Ltd.
6.1.2 B. Braun Melsungen AG
6.1.3 Baxter Healthcare Corporation
6.1.4 BML Parenteral Drugs
6.1.5 Fresenius Kabi AG
6.1.6 Grifols S.A
6.1.7 Pfizer, Inc.
6.1.8 Sichuan Kelun Pharmaceutical Co., Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned
 - Albert David Ltd.
- B. Braun Melsungen AG
- Baxter Healthcare Corporation
- BML Parenteral Drugs
- Fresenius Kabi AG
- Grifols S.A
- Pfizer, Inc.
- Sichuan Kelun Pharmaceutical Co., Ltd.